Antag Therapeutics

About Antag Therapeutics

Antag Therapeutics is a Copenhagen-based biopharmaceutical company pioneering obesity treatment through a novel mechanism known as GIP receptor antagonism. Their lead candidate, AT-7687, is a first-in-class GIPR antagonist peptide evaluated as monotherapy and in combination therapies to achieve meaningful weight loss with tolerability. The company emphasizes personalized and flexible obesity care, aiming to address metabolic dysfunction and related conditions such as diabetes and cardiovascular risk. Its team combines experts in obesity and incretin biology to drive clinical progress and long-term patient health.